Divarasib Bests 1st-Generation KRASG12C Inhibitors.

In previously treated KRAS G12C-mutated non-small cell lung cancer, divarasib reduced the risk of disease recurrence or death by 42% versus first-generation sotorasib or adagrasib.

• Why it matters: Outcomes after standard first-generation KRASG12C inhibition remain limited, creating a need for more effective options in this previously treated patient population.
• What they did: An international phase III trial compared divarasib with standard first-generation drugs sotorasib or adagrasib, with a median follow-up of 14.3 months.
• The result: Median progression-free survival was 9.8 months with divarasib versus 5.7 months with sotorasib or adagrasib, implying improved disease control.